QuickView for PD-173074 (compound)

1. ESC-like cell populations derived from pluripotent epiblast stem cells
2. L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (3 of 4)
3. L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (2 of 4)
4. L1000 CMAP - Hepatocellular carcinoma HEPG2 cells treated with small molecule perturbagens
5. L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (1 of 4)

1. The FGFR inhibitor PD173074 binds to the C-terminus of oncofetal HMGA2 and modulates its DNA-binding…
2. PD173074 blocks G1/S transition via CUL3-mediated ubiquitin protease in HepG2 and Hep3B cells.
3. The FGF receptor inhibitor PD173074 modulates Lefty expression in human induced pluripotent stem cel…
4. NMR backbone assignments of the tyrosine kinase domain of human fibroblast growth factor receptor 3 …
5. FGFR1 selective inhibitor PD173074 can reduce proliferation and induce apoptosis of nasopharyngeal c…

There were no clinical trials for PD-173074